Chugai Pharmaceutical (OTCMKTS:CHGCY) Announces Earnings Results

Chugai Pharmaceutical (OTCMKTS:CHGCY) released its quarterly earnings data on Tuesday. The company reported $0.27 earnings per share (EPS) for the quarter, Zacks reports. Chugai Pharmaceutical had a return on equity of 23.76% and a net margin of 35.09%.

Chugai Pharmaceutical Stock Performance

Shares of CHGCY stock opened at $21.79 on Tuesday. The stock has a fifty day moving average price of $20.75 and a 200 day moving average price of $24.66. The stock has a market cap of $71.72 billion, a PE ratio of 23.41 and a beta of 0.60. Chugai Pharmaceutical has a 1 year low of $18.33 and a 1 year high of $34.84.

Analyst Ratings Changes

CHGCY has been the topic of several research analyst reports. Nomura upgraded shares of Chugai Pharmaceutical to a “hold” rating in a research report on Tuesday, September 1st. UBS Group downgraded shares of Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, Chugai Pharmaceutical has an average rating of “Moderate Buy”.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its operations focus on addressing unmet medical needs through biotechnology, antibody engineering and other advanced drug-discovery technologies.

The company’s principal therapeutic areas include oncology, hematology, immunology, rheumatology, neuroscience, renal diseases and bone disorders. Its portfolio includes medicines such as Actemra (tocilizumab), used in several inflammatory conditions; Hemlibra (emicizumab), a treatment for hemophilia A; Alecensa (alectinib), an oncology medicine; and Enspryng (satralizumab), used for neuromyelitis optica spectrum disorder.

Founded in Japan in 1925, Chugai is headquartered in Tokyo and primarily serves the Japanese market while also commercializing products internationally through its strategic relationship with Roche.